Viyash Scientific Ltd
- Market cap
- ₹ 9,043 Cr.
- P/E
- 40.6x
- P/B
- 3.12x
- 52-week range
- 178.13 – 298
- ROE
- 7%
- ROCE
- 13%
- Dividend yield
- 0%
- Debt / equity
- 0.17
- Sector
- Pharmaceuticals & Biotechnology
- Industry
- Pharmaceuticals
- Listed on
- NSE, BSE
About
Viyash Scientific Limited, formerly SeQuent Scientific Limited, is an India-based integrated pharmaceutical company with a global footprint, operating in the domains of animal health (active pharmaceutical ingredients (APIs), and finished dosage formulations) and analytical services. The Company has eight manufacturing facilities, based in India, Turkey, Brazil, Spain and Germany. It is focused on various therapies, such as targeted are anthelmintics (endo and ecto parasiticides), anti-protozoals, nutraceuticals, nonsteroidal anti-inflammatory drugs (NSAIDs), anti-infectives and dermatology. It specializes in analytical and bioanalytical services to support the API, pharmaceutical, personal care and nutraceutical companies. It offers analytical solutions, including method validation, stability, microbiology for APIs and finished products in a variety of dosage forms as per pharmacopoeia monographs, customer-developed methods or in-house method development.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Pharmaceuticals: 221 companies →Viyash Scientific Ltd against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)40.6 against a typical 34.6: pricier than most peers (1st = cheapest).131st of 220
- Sales growth+19.4% against a typical +15.6% from a year earlier.84th of 197
- Profit growth+113.5% against a typical +18.9% from a year earlier.29th of 160
- Share price, 3 months−11.2% against a typical −0.5%.150th of 200
- Size₹ 9,043.2 Cr. market value against a typical ₹ 507.7 Cr. (1st = largest).42nd of 199
Credit ratings
Every rating action on file, newest first, including reaffirmations. Open a row for the agency's reasoning. All credit rating updates
High safety
Rated AA- by 2 agencies- All agencies agree and none has raised a warning.
| Agency | Current rating | Outlook | As of |
|---|---|---|---|
| ICRA | [ICRA]AA- | Stable | 17 Jun 2026 |
| India Ratings | IND AA-; IND A1+ | Stable | 30 Apr 2026 |
| Rating | Details | |||||
|---|---|---|---|---|---|---|
| 17 Jun 2026 | Reaffirmed | [ICRA]AA- | — | ICRA | ₹ 185 Cr. | |
| 30 Apr 2026 | ▲ Upgrade | IND AA- | — | India Ratings | ₹ 35 Cr. | |
| 22 Apr 2026 | New rating | [ICRA]AA- | — | ICRA | ₹ 185 Cr. |
Board meetings
Results dates and other board meetings. Full calendar
| Details | ||
|---|---|---|
| 11 Aug 2026 | Financial Results | To consider and approve the financial results for the period ended Jun 30, 2026 |
| 19 May 2026 | Financial Results/Dividend | To consider and approve the financial results for the period ended March 31, 2026 and dividend |
| 5 Feb 2026 | Financial Results | To consider and approve the financial results for the period ended December 31, 2025 |
| 14 Nov 2025 | Financial Results | To consider and approve the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and half year ended September 30, 2025. |
| 8 Aug 2025 | Financial Results | To consider and approve the financial results for the period ended Jun 30, 2025 |
| 20 May 2025 | Financial Results/Dividend | To consider and approve the financial results for the period ended March 31, 2025 and dividend |
Financials
Consolidated figures in ₹ crore.
| ₹ Cr. | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 346 | 329 | 361 | 390 | 369 | 774 | 402 | 792 | 850 | 858 | 920 | 946 |
| Expenses | 331 | 307 | 329 | 348 | 330 | 674 | 355 | 673 | 677 | 683 | 736 | 768 |
| Operating Profit | 15 | 22 | 32 | 42 | 39 | 100 | 46 | 119 | 173 | 176 | 184 | 178 |
| OPM % | 4.4% | 7% | 9% | 11% | 11% | 13% | 12% | 15% | 20% | 20% | 20% | 19% |
| Other Income | 10 | 7 | −1 | 3 | 0 | 4 | 1 | 6 | 6 | −27 | 16 | 8 |
| Interest | 13 | 13 | 12 | 16 | 14 | 21 | 15 | 20 | 18 | 17 | 15 | 13 |
| Depreciation | 15 | 15 | 16 | 16 | 17 | 58 | 16 | 56 | 59 | 59 | 60 | 62 |
| Profit before tax | −3 | 1 | 3 | 12 | 8 | 24 | 16 | 48 | 102 | 73 | 125 | 112 |
| Tax % | 123% | −617% | 52% | 24% | 20% | −71% | 36% | 24% | 29% | 34% | 47% | 29% |
| Net Profit | −7 | 11 | 1 | 9 | 6 | 42 | 10 | 37 | 73 | 49 | 66 | 79 |
| EPS in Rs | −0.34 | 0.33 | −0.04 | 0.26 | 0.1 | 1.78 | 0.37 | 1.27 | 2.18 | 0.88 | 1.19 | 1.51 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- 19%
- 5 Years
- 20%
- 3 Years
- 34%
- TTM
- 53%
- 10 Years
- 28%
- 5 Years
- 15%
- 3 Years
- 73%
- TTM
- 148%
- 10 Years
- 9%
- 5 Years
- 2%
- 3 Years
- 46%
- TTM
- —
- 10 Years
- 8%
- 5 Years
- 3%
- 3 Years
- 4%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Viyash Scientific Ltd | ₹ 227.98 | ₹ 9,043 Cr. | 40.6x | 3.1x | 7% | — |
| Sun Pharmaceutical Industries | ₹ 1,743.00 | ₹ 4,18,194 Cr. | 38.4x | 5.6x | 14.2% | 19.1% |
| Divi's Laboratories | ₹ 8,984.00 | ₹ 2,38,497 Cr. | 73.3x | 11.5x | 16.2% | 24.3% |
| Torrent Pharmaceuticals | ₹ 4,482.00 | ₹ 1,70,475 Cr. | 72.7x | 19.2x | 27.1% | 15.3% |
| Cipla | ₹ 1,337.00 | ₹ 1,08,011 Cr. | 27.6x | 3.3x | 11.8% | 13.7% |
| Zydus Lifesciences | ₹ 1,127.85 | ₹ 1,12,503 Cr. | 21.2x | 4.2x | 19.7% | 18.5% |
Management
- Haribabu Bodepudi
- Group Chief Executive Officer, Managing Director
- Ramakant Singani
- Chief Financial Officer
- Rajaram Narayanan
- Chief Executive Officer - Animal Health
- Yoshita Susmit Vora
- Company Secretary and Compliance Officer
- Prasad Lad
- Vice President - Human Resources and Admin
- Nrusimha Srinivasa Rao Bondalapati
- Vice President - Quality & Regulatory
- Pankaj Lohan
- Vice President, Head - India Formulations
- Attanti Veera Venkata Srinivasa Rao
- Vice President - Research & Development (API)
Prices are delayed and for information only. Nothing on this page is investment advice.